GlobalData on MSN21h
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASHEli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
FILE - A sign for Eli Lilly & Co. appears outside their corporate headquarters in Indianapolis on April 26, 2017. (AP Photo/Darron Cummings, File) Eli Lilly’s profit doubled in the fourth ...
(AP Photo/Darron Cummings, File) Eli Lilly’s profit doubled in the fourth ... solid growth for the drugs, Edward Jones analyst John Boylan said in a research note. For 2025, the Indianapolis ...
FILE - A sign for Eli Lilly & Co. appears outside their corporate headquarters in Indianapolis on April 26, 2017. (AP Photo/Darron Cummings, File) (Darron Cummings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback